Safety, pharmacokinetics and pharmacodynamics of VIS649, a humanized monoclonal IgG2 targeting APRIL, for the treatment of IgAN in a GLP toxicology study in Cynomolgus Monkeys
September 27, 2018 | International IgAN Symposium
Susan E Sloan, James R Myette, Bharathi L Sundaresh, Zachary Shriver, David Oldach, Brian J G Pereira